Cimerli Biosimilar Targets Vision Loss in Age-Related Macular Degeneration Through VEGF Inhibition

A biosimilar treatment called Cimerli aims to address vision loss associated with age-related macular degeneration through effective VEGF inhibition. The treatment focuses on preserving eyesight for individuals affected by this condition. Cimerli operates by inhibiting vascular endothelial growth factor (VEGF). Age-related macular degeneration damages the macula, leading to central vision loss, but this treatment is designed to combat that loss. The development offers a potential option for managing this common age-related eye disease.

Newsflash | Powered by GeneOnline AI
Date: May 1, 2025

Related posts:

Ignoring Intuition Increases Self-Blame, Study Finds Liposomal Annamycin Shows Synergistic Activity Against Leukemia, Lymphoma, Breast, Lung, and Colon Cancers in Preclinical Models When Combined with Chemotherapies Pharma M&A Deal Value Jumps 101% in Q1 2025, Fueled by Oncology Focus European Commission Invests $565 Million to Strengthen Scientific Workforce Amid Global Competition

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後